Crossmark

1336 Final Ph1b/2 results for nous-209 monotherapy in lynch syndrome carriers: annual revaccination boosts T cell immunity informing future cancer interception strategies

Crossref DOI link: https://doi.org/10.1136/jitc-2025-SITC2025.1336

Published Online: 2025-11-07

Published Print: 2025-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Morena D’Alise, Anna

Willis, Jason

Hall, Michael

Cruz-Correa, Marcia

Idos, Gregory E

Thirumurthi, Selvi

Ballester, Veroushka

Leoni, Guido

Garzia, Irene

Antonucci, Laura

Marco, Lorenzo De

Micarelli, Elisa

Gogov, Sven

Dong, Wenli

Jack Lee, J

Vornik, Lana A

Garcia-Gonzalez, Araceli

Uribe, Laura Reyes

Richmond, Ellen

Umar, Asad

Brown, Powel

Rodriguez, Luz Maria

Scarselli, Elisa

Vilar, Eduardo
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05078866 at ClinicalTrials.gov

Documents that mention this clinical trial

SITC strategic vision: prevention, premalignant immunity, host and environmental factors
https://doi.org/10.1136/jitc-2024-010419

1336 Final Ph1b/2 results for nous-209 monotherapy in lynch syndrome carriers: annual revaccination boosts T cell immunity informing future cancer interception strategies
https://doi.org/10.1136/jitc-2025-sitc2025.1336

Discovery and validation of frameshift-derived neopeptides in Lynch syndrome: paving the way for novel cancer prevention strategies
https://doi.org/10.1136/jitc-2024-011177

Advances and challenges in cancer immunoprevention and immune interception
https://doi.org/10.1136/jitc-2023-007815
License Information

License valid from 2025-10-31

Document is current

Any future updates will be listed below